Literature DB >> 23978293

PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study.

Randi V Karlsen1, Signe B Larsen, Jane Christensen, Klaus Brasso, Søren Friis, Anne Tjønneland, Susanne Oksbjerg Dalton.   

Abstract

BACKGROUND: Social differences in prostate cancer (PC) incidence and mortality might be related to testing for prostate-specific antigen (PSA). Although routine PSA screening is not recommended in Denmark, testing without clinical indication increased during the past decade. We evaluated associations between socio-demographic or clinical characteristics and PSA testing without clinical indication.
MATERIAL AND METHODS: In the Danish Diet, Cancer and Health Cohort, we identified 1051 men with PC diagnosed in 1993-2008. Diagnostic and clinical characteristics were obtained from medical records, and socio-demographic information was retrieved from administrative registers. We used general logistic regression analysis to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between socio-demographic or clinical characteristics and PSA testing without clinical indication. Cox regression analysis was used to examine associations with mortality.
RESULTS: PSA testing without clinical indication was less likely among patients > 67 years (OR 0.7; 0.5-1.0). Men who were, PSA tested without clinical indication, were more likely to have vocational training (OR 1.8; 1.1-2.9) or higher education (OR 1.5; 0.9-2.5) and less likely to have advanced disease (OR 0.6; 0.4-0.9). PSA testing without clinical indication more often preceded therapy with curative intent (OR 1.8; 1.1-2.9) and less often palliative treatment (OR 0.6; 0.3-1.0). Men who were PSA tested without clinical indication had non-significantly lower overall and PC-specific mortality [hazard ratios 0.8 (0.5-1.2) and 0.6 (0.3-1.1), respectively].
CONCLUSIONS: PSA testing without clinical indication was associated with higher educational level. PC detected by PSA testing with no clinical indication was more often localized and treated with curative intent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23978293     DOI: 10.3109/0284186X.2013.831474

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

Review 1.  A stage-dependent link between metabolic syndrome components and incident prostate cancer.

Authors:  Jan Hammarsten; Jan-Erik Damber; Mohammad A Haghsheno; Dan Mellström; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

2.  Prescription rates for commonly used drugs before and after a prostate cancer diagnosis.

Authors:  Signe Benzon Larsen; Christian Dehlendorff; Charlotte Skriver; Anton Pottegård; Søren Friis; Martin Andreas Røder; Klaus Brasso; Anne Katrine Duun-Henriksen
Journal:  Cancer Causes Control       Date:  2022-01-10       Impact factor: 2.506

3.  Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark.

Authors:  Marc Casper Meineche Andersen; Hein Vincent Stroomberg; Klaus Brasso; John Thomas Helgstrand; Andreas Røder
Journal:  Diagnostics (Basel)       Date:  2022-05-19

4.  Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients.

Authors:  Gennady M Zharinov; Oleg A Bogomolov; Natalia N Neklasova; Vladimir N Anisimov
Journal:  Oncoscience       Date:  2017-02-24

5.  Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients.

Authors:  Jianguang Ji; Jan Sundquist; Kristina Sundquist
Journal:  Nat Commun       Date:  2018-06-18       Impact factor: 14.919

6.  Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations.

Authors:  Christel Häggström; Tanja Stocks; Gabriele Nagel; Jonas Manjer; Tone Bjørge; Göran Hallmans; Anders Engeland; Hanno Ulmer; Björn Lindkvist; Randi Selmer; Hans Concin; Steinar Tretli; Håkan Jonsson; Pär Stattin
Journal:  Epidemiology       Date:  2014-11       Impact factor: 4.822

7.  Prostate specific antigen test uptake: a cross sectional study on elderly men in Western Iran.

Authors:  Mehdi Mirzaei-Alavijeh; Farzad Jalilian; Laleh Solaimanizadeh; Abdollah Saadatfar; Shima Khashij; Razieh Pirouzeh; Farzaneh Solaimanizadeh
Journal:  BMC Geriatr       Date:  2020-08-24       Impact factor: 3.921

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.